Introduction: Hidradenitis suppurativa (HS) is a serious, debilitating, chronic inflammatory skin disease. Adalimumab is a fully human, immunoglobulin G1 monoclonal antibody specific for tumor necrosis factor-alpha...
Areas covered: This manuscript summarizes the current evidence on chemistry, pharmacodynamics, pharmacokinetics, as well as clinical efficacy, safety and tolerability of the currently approved biologic drug adalimumab in the treatment of active moderate to severe HS in adults.
Objective: To evaluate the efficacy and safety of adalimumab, an anti-tumor necrosis factor-α antibody, in patients with moderate to severe HS.
The FDA has approved Humira (adalimumab), from AbbVie, for the treatment of moderate to severe hidradenitis suppurativa (HS). It is...
Clinical practices for hidradenitis suppurativa (HS) are rapidly evolving because of increased attention to HS in recent years and ongoing research on disease pathophysiology and optimal treatments.
Adalimumab (ADA) is the only Food and Drug Administration‒approved treatment for moderate-to-severe hidradenitis suppurativa, whereas etanercept and certolizumab-pegol have been shown to be ineffective, suggesting that the mechanism of action of ADA is distinct in hidradenitis suppurativa and may contribute to improved wound healing.
AbbVie has announced that Humira (adalimumab) is EU approved for the treatment of active moderate to severe hidradenitis suppurativa (acne...
In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed efficacy against hidradenitis suppurativa.
Objectives: To identify clinical parameters predicting response to adalimumab and confirm its efficacy/safety.
Until very recently, hidradenitis suppurativa (HS) was largely ignored by medical regulators, the pharmaceutical industry and society in general.